Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (301-310 of 713) with videos related to

Pageof 72
Sort By:
Cancer|April 28, 2011
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinibAlfonso Quintás-Cardama, Hagop Kantarjian, Jianqin Shan, et al.
Blood Advances|January 4, 2018
Co-occurrence of <i>FLT3</i>-TKD and <i>NPM1</i> mutations defines a highly favorable prognostic AML groupPrajwal Boddu, Hagop Kantarjian, Gautam Borthakur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosisConstantine S Tam, Hagop Kantarjian, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 18, 2011
Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implicationsAli Al Ameri, Elias Jabbour, Guillermo Garcia-Manero, et al.
Blood|October 30, 2010
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failureElias Jabbour, Hagop Kantarjian, Susan O'Brien, et al.
Cancer|June 24, 2005
Outcome of patients with acute myelogenous leukemia after second salvage therapyFrancis Giles, Susan O'Brien, Jorge Cortes, et al.
Cancer|April 30, 2005
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986Rashid Saba, Elias Jabbour, Francis Giles, et al.
International Journal of Implant Dentistry|November 28, 2022
Anatomical variations and accessory structures in the maxilla in relation to implantological procedures: an observational retrospective study of 212 cases using cone-bean computed tomographyAugusto Cimolai-de la Encina, Natalia Martínez-Rodríguez, Ricardo Ortega-Aranegui, et al.
Cancer|September 13, 2007
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failureJorge Cortes, Alfonso Quintás-Cardama, Guillermo Garcia-Manero, et al.
Cancer|June 15, 2007
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicityElias Jabbour, Jorge Cortes, Hagop Kantarjian, et al.
Pageof 72

Showing results (301-310 of 713) with videos related to

Sort By:
Pageof 72
Cancer|April 28, 2011
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinibAlfonso Quintás-Cardama, Hagop Kantarjian, Jianqin Shan, et al.
Blood Advances|January 4, 2018
Co-occurrence of <i>FLT3</i>-TKD and <i>NPM1</i> mutations defines a highly favorable prognostic AML groupPrajwal Boddu, Hagop Kantarjian, Gautam Borthakur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosisConstantine S Tam, Hagop Kantarjian, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 18, 2011
Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implicationsAli Al Ameri, Elias Jabbour, Guillermo Garcia-Manero, et al.
Blood|October 30, 2010
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failureElias Jabbour, Hagop Kantarjian, Susan O'Brien, et al.
Cancer|June 24, 2005
Outcome of patients with acute myelogenous leukemia after second salvage therapyFrancis Giles, Susan O'Brien, Jorge Cortes, et al.
Cancer|April 30, 2005
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986Rashid Saba, Elias Jabbour, Francis Giles, et al.
International Journal of Implant Dentistry|November 28, 2022
Anatomical variations and accessory structures in the maxilla in relation to implantological procedures: an observational retrospective study of 212 cases using cone-bean computed tomographyAugusto Cimolai-de la Encina, Natalia Martínez-Rodríguez, Ricardo Ortega-Aranegui, et al.
Cancer|September 13, 2007
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failureJorge Cortes, Alfonso Quintás-Cardama, Guillermo Garcia-Manero, et al.
Cancer|June 15, 2007
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicityElias Jabbour, Jorge Cortes, Hagop Kantarjian, et al.
Pageof 72